Beam Therapeutics vs Microbiotica

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (38 vs 39)
Beam Therapeutics logo

Beam Therapeutics

GrowthBiotechnology

Base Editing Gene Therapy

Beam Therapeutics develops precision genetic medicines using base editing technology that makes single-letter DNA changes without cutting the double helix.

AI VisibilityBeta
Overall Score
D38
Category Rank
#1 of 1
AI Consensus
64%
Trend
up
Per Platform
ChatGPT
44
Perplexity
34
Gemini
29

About

Beam Therapeutics is a genetic medicines company founded in 2017 by base editing pioneers David Liu, J. Keith Joung, and Feng Zhang, having raised over $600M and gone public on Nasdaq. The company is built around base editing, a technology that makes precise single nucleotide changes in DNA without creating double-strand breaks, reducing the risk of unintended insertions or deletions compared to traditional CRISPR. Beam is developing a portfolio of base editing medicines targeting blood disorders, liver diseases, and immuno-oncology, including sickle cell disease, beta-thalassemia, and various cancers. The company also employs prime editing, a newer and even more precise gene editing modality for more complex genetic changes. Beam's pipeline includes both in vivo therapies delivered directly into the body and ex vivo cell therapy approaches where patient cells are edited outside the body and reinfused. As a clinical-stage company, Beam has programs in IND-enabling and Phase 1 trials and represents one of the most advanced next-generation gene editing platforms in development.

Full profile
Microbiotica logo

Microbiotica

EmergingBioTech

Microbiome Therapeutics

Microbiotica raised $105M Series C in 2025 for its gut microbiome platform linking bacterial strains to disease, enabling live biotherapeutic products for cancer immunotherapy and IBD.

AI VisibilityBeta
Overall Score
D39
Category Rank
#1 of 2
AI Consensus
75%
Trend
up
Per Platform
ChatGPT
47
Perplexity
43
Gemini
47

About

Microbiotica applies genomics and machine learning to map the gut microbiome's causal role in disease, then develops live biotherapeutic products (LBPs) targeting the specific bacterial strains responsible. The company's Reference Microbiome database — built from thousands of patient samples — is the world's most comprehensive catalog of gut bacteria linked to disease outcomes, providing a systematic foundation for microbiome drug discovery.

Full profile

AI Visibility Head-to-Head

38
Overall Score
39
#1
Category Rank
#1
64
AI Consensus
75
up
Trend
up
44
ChatGPT
47
34
Perplexity
43
29
Gemini
47
30
Claude
42
34
Grok
37

Key Details

Category
Base Editing Gene Therapy
Microbiome Therapeutics
Tier
Growth
Emerging
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Beam Therapeutics
Base Editing Gene Therapy
Only Microbiotica
Microbiome Therapeutics

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.